摘要
目的:探讨调强放疗联合紫杉醇每周给药的方法治疗食管癌的近期疗效、局部控制率、生存率及毒性反应。方法:103例食管癌患者随机分为60例放化组(调强放疗+紫杉醇组),43例单放组(单纯调强放疗组)。单放组:采用调强放疗,95%PTV:66GY/30-33次,每周5次;放化组:调强放射治疗同时化疗(紫杉醇60mg)第1、8、15、22、29、36天静滴。结果:放化疗组的食管癌病灶近期总有效率为8 3.3%,单纯放疗组为60.4%,两组差异有显著性(P<0.05)。1、2年生存率,单放组为55.8%(24/43)、32.5%(14/43),同步放化组为86.6%(52/60)、68.3%(41/60),两组差异有显著性(P<0.05)。不良反应放化组稍高于单放组,但两者差异无统计学意义。结论:调强放疗联合紫杉醇单药每周方案,同步治疗食管癌近期疗效和局部控制率较好,能提高远期生存率可能,虽毒性反应增加但能耐受。
Objective：To evaluate the short -term efficacy, local control rate, survival rate and toxicity of concur- rent paclitaxel chemotherapy and IMRT for esophageal carcinoma. Methods：All 103 esophageal carcinoma patients were randomized in two groups： 60 cases was treated with concurrent IMCRT and paclitaxel chemotherapy（ chemo - radiation group） ; 43 cases with radiotherapy only（ radiotherapy group）. All patients were irradiation 2.0Gy/per frac- tion by planning target volume（PTV） 95% , five fractions a week, the total radiation dose was 66Gy in tumor. Be- sides, the chemo - radistion group was also received concurrent chemotherapy with 60mg of paclitaxel every Monday during radotherapy. Results： The chemo - radiation group was more effective than radiotherapy group, and there was significant difference between 2 groups （P 〈 0.05 ）. 1 - year, 2 - year survival rates of chemo - radiation group and radiation group were 86.6%, 68.3% and 55.8%, 32.5%, respectively （P 〈 0.05）. Conclusion ： Concurrent pacli- taxel chemotherapy and intensity modulated radiation therapy （IMRT） for esophageal carcinoma can improve the short - term efficacy and local control rate, improve the long - term survival rate with lightly higher and tolerable toxicity.
出处
《现代肿瘤医学》
CAS
2012年第7期1381-1383,共3页
Journal of Modern Oncology
基金
承德市科学技术研究与发展计划项目(编号:201121067)
关键词
食管癌
调强放疗
化疗
esophaglal cancer
IMRT
chemotherapy
